Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform

Table 3 KRAS agreement study between GeneReader and Pyrosequencing and Therascreen PCR Assays

>5% KRAS variant allele frequency cut off		Pyrosequencing and Therascreen PCR Assays^(a)
>5% KRAS variant allele frequency cut off		(MT)	(WT)	Total
GeneReader NGS System^(b)	(MT)	14	0	14
	(WT)	0	29	29
	Total	14	29	43

^(a)If KRAS is mutant by Therascreen KRAS RGQ PCR assay or Therascreen RAS extension Pyrosequencing assay, the condition is recorded as a mutant (MT)
^(b)For Actionable Insights Tumor Panel, a 5% allelic frequency cut off was used to call variants for codon 12, 13, 59, 61, 117 and 146, which are addressed by established QIAGENTherascreen PCR assays

ISSN: 1471-2407